About OPHIREX, INC
Ophirex is a Public Benefit Corporation developing the first oral treatment for snakebite, focusing on addressing the medical needs associated with life-threatening envenomation. The company's investigational candidate, varespladib, is a first-of-its-kind oral rescue treatment that inactivates a key toxin present in the venom of over 95% of snake species.
Developing first-of-its-kind oral treatment for snakebiteCreating portable, immediate post-bite treatmentTargeting a key toxin present in venom of over 95% of snake species
Recent Federal Awards
| Award | Agency | Amount | Date |
|---|---|---|---|
| DHA PH II SEQL PROPOSAL H2S-0045, TITLE: BROAD-SPECTRUM SNAKEBITE ANTIDOTE: METALLOPROTEASE INHIBITION TO IMP | Department of Defense | $1.3M | |
| FOLLOW ON PHASE III RESEARCH AND DEVELOPMENT SBIR FOR PROJECT TITLED, BROAD-SPECTRUM SNAKEBITE ANTIDOTE: ORAL | Department of Defense | $23.4M | |
| Federal contract award | Department of Defense | $9.9M | |
| ARMY MEDICAL RESEARCH AND DEVELOPMENT SBIR PHASE III CONTRACT TITLED ADVANCEMENT OF ADVANCEMENT BROAD-SPECTRUM | Department of Defense | $9.4M |
Is this your company?
Claim this profile to keep it accurate — and see the federal & state opportunities GovIntel's AI has matched to OPHIREX, INC right now.
Claim this profile See matched opportunitiesData compiled from public government sources including SAM.gov, USAspending.gov, and state procurement records. Last verified against federal award records. Inaccurate? Let us know.